1.5.19

The Board Meeting series is designed to open minds and explore new trends that will translate into more effective governance and success throughout the life science industry.  The Board Meeting WEST is an exclusive, invite-only, off the record meeting for life science board members to discuss key issues and solve problems in an interactive and productive setting.

west-background.jpg

SPONSORS

 
 
 
 

SPONSORSHIP OPPORTUNITIES

Sponsors gain access in an intimate and private setting with life science industry top leaders and decision makers.

For additional information, please contact Susan Grayson at susan@crushlifesicences.com or sponsor@crushlifesciences.com.

AGENDA

8:00 - 8:45 am
Registration and Networking Breakfast

8:45 - 9:00 am
Opening Remarks

9:00 - 9:45 am
Building the Right Board
Cheryl Blanchard
, President & CEO, Keratin Biosciences; Jeff Jonker, Board Director, NGM BIO; Gail Maderis, President & CEO, Antiva Biosciences
Moderator: Rachael Bushey, Partner & Chair of Life Sciences, Pepper Hamilton LLP

9:45 - 10:30 am
Fireside Chat: Corporate Responsibility
David Beier
, Managing Director, Bay City Capital
Moderator: Chris Earl, President, Innotrove and Senior Advisor, International AIDS Vaccine Initiative

10:30 - 10:45 am
Networking Break

10:45 - 11:30 am
Forcing Diversity on the Board – Point-Counter Point
Laura Brege
, former CEO, Nodality and former COO, Onyx Pharmaceuticals; Nina Kjellson, Partner, Canaan Partners; Catherine Sohn, former SVP, GlaxoSmithKline and Board Director, Jazz Pharmaceuticals
Moderator: Laurie Halloran, President & CEO, Halloran Consulting Group

11:30 - 12:15 pm
View from the Board: Responding to an Acquisition Offer
Stephen Sands
, Vice Chairman Investment Banking and Chairman Global Healthcare Group, Lazard and Cliff Stocks, CEO, OncoResponse

 

12:15 - 1:15 pm
Networking Lunch

1:15 - 2:15 pm
KEYNOTE PART 1 – Marilyn Nagel, Partner, Boardwise
2-hour session including interactive discussions, lively conversation and best practice sharing
#Never Me, #Never Here
– Board’s responsibilities for ensuring corporate leaders protect employees, vendors and contractors in this era of heightened awareness around sexual harassment in the workplace. How can directors address it? Too often, attention to this doesn’t become clear until after “bad things” happen.

2:15 - 2:30 pm
Networking Break

2:30 - 3:30 pm
KEYNOTE PART 2 – Marilyn Nagel, Partner, Boardwise

3:30 - 4:15 pm
Proactively Managing Board Dynamics and Transitions
Christine Bunt
, Chairman & CEO, Verseau Therapeutics and Ivana Magovcevic-Liebisch, EVP & Chief Business Officer, Ipsen

4:15 - 5:00 pm
Surprise Premier Napa Wine Tasting Event

5:00 - 6:00 pm
Networking Cocktail Reception

 

STEPHEN SANDS
Vice Chairman of Investment Banking and Chairman of the Global Healthcare Group at Lazard

Stephen Sands, Vice Chairman of Investment Banking and Chairman of the Global Healthcare Group at Lazard, has built a 25-year career providing strategic and financial advice to senior executives and boards of directors at leading healthcare and life sciences companies globally. Prior to joining Lazard, a financial advisory and asset management firm, Stephen was a Partner in the health care practice of McKinsey & Company. During his career, he has co-founded two life sciences companies: Enzytech (acquired by Alkermes) and Opta Food Ingredients (acquired by Stake Technology). Stephen has also served as director on the boards of several life sciences companies, including National Imaging Associates, Inc. (Acquired by Magellan Health Services company) and Isogen LLC (acquired by Monsanto). He currently is a director on the board of Cognition Therapeutics (Alzheimer’s disease).

Sands_Stephen_2492 low-res.JPG
crush-background.jpg